Inovio's INO-3107 BLA review advances toward October 30 PDUFA date
Inovio said the FDA has not yet weighed in on accelerated approval eligibility for INO-3107 but expects feedback on the confirmatory trial design, as it reported second-quarter 2026 results.
SEC filing